Key result
In dogs with chronic coronary stenosis, UL-FS 49 prevented the exercise-induced decrease in systolic wall thickening in the ischemic zone (21.5% during run vs 9.3% in control run).
Why the study?
Does the bradycardiac agent UL-FS 49 prevent exercise-induced regional myocardial dysfunction in dogs with chronic coronary stenosis?
Does the bradycardiac agent UL-FS 49 prevent exercise-induced regional myocardial dysfunction in dogs with chronic coronary stenosis?
Absolute Event Rate: 21.5% vs 9.3%
The bradycardiac agent UL-FS 49 prevents exercise-induced regional myocardial dysfunction in a canine model of chronic coronary stenosis by limiting the exercise-induced increase in heart rate.
No takes yet. Share an insight, caveat, or question.
May support bradycardic strategies in ischemic dysfunction; leaves open translation to human coronary disease.
Guth et al. (1987) studied chronic coronary artery stenosis (n=10). UL-FS 49 vs. Control treadmill exercise bout was evaluated on Systolic wall thickening (%WT) in the poststenotic myocardium during exercise. In dogs with chronic coronary stenosis, UL-FS 49 prevented the exercise-induced decrease in systolic wall thickening in the ischemic zone (21.5% during run vs 9.3% in control run).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: